公开(公告)号：US20220195437A1

公开(公告)日：2022-06-23

申请号：US17643807

申请日：2021-12-10

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Dae-Shik KIM ,  Hyeong-Wook CHOI ,  Francis G. FANG ,  Yoshinori TAKAHASHI ,  Kenji KIKUTA ,  Hikaru YOSHIMURA ,  Wataru ITANO ,  Toshiki KUROKAWA ,  Ryo DAIRIKI ,  Zhi ZHOU ,  Mingde SHAN

IPC: C12N15/113 ,  A61K31/712 ,  A61P25/28

Abstract: Antisense oligonucleotides are provided. These antisense oligonucleotides are useful in the preparation of gapmers for inhibition of Tau mRNA transcription. Inhibition of Tau mRNA transcription may result in decrease of amounts of Tau protein in a subject, allowing treatment of diseases and disorders related to expression of Tau, including Alzheimer's disease and primary tauopathies.

公开(公告)号：US20210123919A1

公开(公告)日：2021-04-29

申请号：US17052133

申请日：2019-05-13

Applicant: Merck Sharp & Dohme Corp. ,  Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro FUNAHASHI ,  Kotaro KODAMA ,  Ryo DAIRIKI ,  Yukinori MINOSHIMA

IPC: G01N33/574 ,  A61K31/47 ,  A61K39/395 ,  C07K16/28 ,  A61P35/00

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a combination therapy comprising lenvatinib compound and a PD-1 antagonist. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing cancer.